

2Q23

CG Global Healthcare Practice



Canaccord Genuity Expands Global Healthcare Practice Significantly in the Last 18 Months

RECENT INVESTMENTS IN THE HEALTHCARE TEAM HAVE EXPANDED CAPABILITIES IN DIGITAL HEALTH, HEALTHCARE IT, PHARMA SERVICES, AND OTHER AREAS

Selected Recent Healthcare Transactions
















Global Health and Wellness M&A























Healthcare Equity Capital Markets















\$116,620,560 Follow-on Offering Passive Bookrunner

January 2023



\$135.100.000 Passive Bookrunner

November 2022

reunion

\$10.000.000 Sole Agent

November 2022



\$460,000,000 Follow-on Offering Co-Manager

November 2022

ak∈ro \$230,000,000 Follow-on Offering Lead Manager September 2022

Ranked #1 by PitchBook for Global Digital & Tech-Enabled Healthcare Advisory¹

Rank	Firm Name	# of Transactions LTM 3/31/23	Rank	Firm Name	# of Transactions 2020-2022
1	Canaccord Genuity	12	1	Canaccord Genuity	33
2	Houlihan Lokey	4	2	William Blair	19
3	Lincoln International	3	3	TripleTree	17
4	Robert W Baird	2	4	Lincoln International	10
4	MTS Health Partners	2	4	Houlihan Lokey	10
4	TripleTree	2	5	Ziegler	9
4	AGC Partners	2	6	Jefferies Financial	7
4	Jefferies Financial	2	6	Raymond James	7
4	Guggenheim Partners	2	6	Piper Sandler	7
5	Westcove Partners	1	6	Goldman Sachs	7



2Q23

CG Global Healthcare Practice



Strengthening the US Team

Canaccord Genuity has made significant investments in its **Healthcare Investment Banking Group** in the past 18 months. Most recently, the firm has promoted two senior bankers within its middle market-focused, M&A advisory practice specializing in healthcare technology and tech-enabled services companies supporting the Provider and Pharma ecosystems.



Nashville-based **Dudley Baker**, a Managing Director who has been with Canaccord Genuity for eight years, has been named Head of Digital & Tech-Enabled Healthcare Banking.



New York City-based **Matthew Kebel**, who has more than a decade of experience in Healthcare and Tech investment banking, including more than five years with the firm, has been promoted to Managing Director.

Canaccord Genuity's other Healthcare banking practices – MedTech & Diagnostics, Biotech & Specialty Pharma, and Cannabis – also continued to strengthen their benches.



Managing Director **Meredith Sondler-Bazar**, with more than 15 years of healthcare banking experience, joined the Biotech & Specialty Pharma practice in New York in 2022.

Canaccord Genuity completed the acquisition of leading Consumer-focused M&A advisory firm Sawaya Partners at the end of 2021. **CG Sawaya's Health & Wellness** practice complements the firm's Healthcare Banking team.



Managing Director **Irina Adler**, who has more than twenty years of investment banking experience, joined the CG Sawaya Health & Wellness practice in early 2023.

International Expansion – Acquisition of Results



The firm's US-based Tech-Enabled Healthcare team was supplemented in July 2022 by the acquisition of UK-based **Results International Group LLP**, a leading European M&A firm specializing in Technology and Healthcare. The addition of the London-based group has expanded Canaccord Genuity's European activities significantly. CG Results is led by **Julie Langley**, Head of Technology and Healthcare Advisory for UK & Europe, with the support of another six senior Healthcare-focused senior bankers, as well as an extensive team.



Julie Langley
Managing Director, Head of Tech
& Healthcare Advisory,
UK & Europe



Kevin Bottomley Managing Director



Kunal Kadiwar Managing Director



David Sanders Managing Director



Issac Jacob Director



Achim Newrzella Director



Tim Sturgeon Director



CG Global Healthcare Practice



Canaccord Genuity Healthcare Investment Banking Team

Jeff Barlow

President, Canaccord Genuity LLC (US) Med Tech & Diagnostics Boston ibarlow@cqf.com

2Q23

Steve Winokur

Managing Director, Global Head of Cannabis & Canadian Healthcare Investment Banking Toronto swinokur@cqf.com

Eugene Rozelman

Managing Director, Co-Head of US Healthcare, Biotech & Specialty Pharma New York erozelman@cgf.com

Dennis Camporeale

Managing Director Med Tech & Diagnostics New York dcamporeale@cgf.com

Julie Langley

Managing Director, Head of Tech & Healthcare Advisory, UK & Europe London jlangley@cgf.com

Dudley Baker

Managing Director, Head of Digital & Tech-Enabled Healthcare Nashville rdbaker@cgf.com

Matt Steere

Managing Director, Co-Head of US Healthcare, Med Tech & Diagnostics San Francisco msteere@cgf.com

Kunal Kadiwar

Managing Director UK & Europe Healthcare London kkadiwar@cgf.com

Slava Leykind

Managing Director, Co-Head of US Consumer Investment Banking - Health & Wellness New York sleykind@cgf.com

Tom O'Connor

Managing Director, Co-Head of US Healthcare IB New York toconnor@cgf.com

Kevin Bottomley

Managing Director UK & Europe Healthcare London kbottomley@cgf.com

Matthew Kebel

Managing Director Digital Health, Healthcare, Media, Marketing, and Info Services New York mkebel@cgf.com

David Sanders

Managing Director UK & Europe Healthcare London dsanders@cgf.com

Meredith Sondler-Bazar

Managing Director Biotech & Specialty Pharma New York msondlerbazar@cgf.com

Financial Sponsors Coverage

Isaiah Knouff

Managing Director, Co-Head of Financial Sponsors Coverage Nashville iknouff@cqf.com

Amy LaBan, CFA

Managing Director, Co-Head of Financial Sponsors Coverage Chicago alaban@cqf.com

Bryan Cummings

Managing Director **US Financial Sponsors Coverage** New York bcummings@cqf.com



2Q23

CG Global Healthcare Practice



About Canaccord Genuity Group Inc.: Through its principal subsidiaries, Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional, and corporate clients through comprehensive investment solutions, brokerage services, and investment banking services. The Company has Wealth Management offices located in Canada, the UK, Guernsey, Jersey, the Isle of Man, and Australia. The international capital markets division operates in North America, the UK & Europe, Asia, Australia, and the Middle East. Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX.

This document is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the securities discussed in this document may not be eligible for sale in some jurisdictions. This document is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. Investors should obtain advice based on their own individual circumstances before making an investment decision.

To the fullest extent permitted by law, neither Canaccord Genuity, nor its affiliates nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained in this document.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information is available on request.

Copyright ©Canaccord Genuity LLC, 2023. Member FINRA/SIPC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity, a division of Canaccord Genuity Group Inc., Canaccord Genuity Limited, and Canaccord Genuity LLC None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.